The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Eric J. Feldman

Weill Medical College of Cornell University and New York Presbyterian Hospital

525 East 68th St

New York

NY 10021



Name/email consistency: high



  • Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA. 2003 - 2011
  • Division of Hematology and Medical Oncology, Weill-Cornell Medical College, New York, NY 10021, USA. 2008
  • The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, USA. 2003


  1. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Feldman, E.J., Lancet, J.E., Kolitz, J.E., Ritchie, E.K., Roboz, G.J., List, A.F., Allen, S.L., Asatiani, E., Mayer, L.D., Swenson, C., Louie, A.C. J. Clin. Oncol. (2011) [Pubmed]
  2. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Feldman, E.J., Cortes, J., DeAngelo, D.J., Holyoake, T., Simonsson, B., O'Brien, S.G., Reiffers, J., Turner, A.R., Roboz, G.J., Lipton, J.H., Maloisel, F., Colombat, P., Martinelli, G., Nielsen, J.L., Petersdorf, S., Guilhot, F., Barker, J., Kirschmeier, P., Frank, E., Statkevich, P., Zhu, Y., Loechner, S., List, A. Leukemia (2008) [Pubmed]
  3. Farnesyltransferase inhibitors in myelodysplastic syndrome. Feldman, E.J. Curr. Hematol. Malig. Rep (2006) [Pubmed]
  4. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Feldman, E.J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G.J., Miller, C., Chopra, R., Jurcic, J.C., Brown, R., Ehmann, W.C., Schulman, P., Frankel, S.R., De Angelo, D., Scheinberg, D. J. Clin. Oncol. (2005) [Pubmed]
  5. Monoclonal antibody therapy in acute myeloid leukemia. Feldman, E.J. Curr. Hematol. Rep. (2003) [Pubmed]
  6. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A., Silver, R.T. Exp. Hematol. (2003) [Pubmed]
WikiGenes - Universities